Amylyx’s ALS disappointment; Lilly’s Alzheimer’s delay; Bayer stays put; Novo Nordisk’s GLP-1 streak; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

End­points News is once again look­ing to high­light LGBTQ+ lead­ers in bio­phar­ma across a va­ri­ety of roles. I en­cour­age you to read Kyle LaHu­cik’s heart­felt note on why we’re con­tin­u­ing this spe­cial re­port for a third year. It al­so de­tails how you can nom­i­nate some­one for the re­port.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.